Description and study of the steroid Metabolome in mucinous ovarian cancer

Characterisation of the STEroid Metabolome in mucinous OVArian cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN21041967

Enrollment

340

Registered

2026-03-17

Start date

2025-09-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mucinous ovarian cancer, mucinous appendiceal and pseudomyxoma peritonei cancer. Cancer

Interventions

Study 1 The first sub-study is a multicentre prospective study to investigate urinary steroid profiling in mucinous cancer, mucinous benign and borderline tumours. 265 individuals will be recruited in

Eligibility

Sex/Gender

Female

Age

18 Years to 120 Years

Inclusion criteria

Inclusion criteria: Women over the age of 18 years with capacity to give informed consent and from the following patient groups: Sub-Study 1 - Diagnostic: 1.1. Participants undergoing surgery for adnexal masses. 1.2. Participants with confirmed biopsy of mucinous ovarian cancer prior to start of treatment. Sub-Study 2 – Follow-up: 2.1. Participants with a confirmed histological biopsy diagnosis of primary mucinous ovarian cancer after completion of first-line treatment. Sub-Study 3 – Appendiceal/ pseudomyxoma peritonei Cancer 3.1. Participants with a pre-operative clinical radiological diagnosis of pseudomyxoma peritonei. 3.2. Participants with a confirmed histological diagnosis of low grade appendiceal mucinous neoplasm (LAMN) and appendiceal carcinomas (excluding non-mucin-producing and neuroendocrine tumours).

Exclusion criteria

Exclusion criteria: Sub-Study 1: 1.1. Participants lacking capacity to consent. 1.2. Using hormonal contraception / implant within last 3 months. 1.3. Used Hormone Replacement Therapy or GnRH analogues in last 3 months. 1.4. Used steroid treatment in last 3 months including inhalers. 1.5. Commenced chemotherapy treatment for ovarian carcinoma. 1.6. Undergoing delayed debulking surgery for ovarian cancer after chemotherapy. Sub-Study 2: 2.1. Participants lacking capacity to consent. 2.2. Using hormonal contraception / implant in last 3 months. 2.3. Used HRT or GnRH analogues in last 3 months. 2.4. Used steroid treatment in last 3 months including inhalers. Sub-Study 3: 3.1. Participants lacking capacity to consent.

Design outcomes

Primary

Measure	Time frame
Expression of steroidogenic genes, enzymes and metabolites from the ovaries. This will be measured from the output of 24 hour urine samples collected from patients. For study 1 - The urinary steroid metabolome will be profiled via GC-MS and other technologies to determine the “steroid fingerprint” in MOC, MBT, and benign ovarian tumours. For study 2 - The urinary steroid metabolome in confirmed MOC will be profiled via GC-MS and other technologies to determine if steroid profiles change during follow-up or at recurrence. For study 3 - The urinary steroid metabolome will be profiled via GC-MS and other technologies to determine the “steroid fingerprint” in MOC, MBT, benign ovarian tumours, and mucinous appendiceal or pseudomyxoma peritoneal cancer.	—

Measure

Time frame

Expression of steroidogenic genes, enzymes and metabolites from the ovaries. This will be measured from the output of 24 hour urine samples collected from patients. For study 1 - The urinary steroid metabolome will be profiled via GC-MS and other technologies to determine the “steroid fingerprint” in MOC, MBT, and benign ovarian tumours. For study 2 - The urinary steroid metabolome in confirmed MOC will be profiled via GC-MS and other technologies to determine if steroid profiles change during follow-up or at recurrence. For study 3 - The urinary steroid metabolome will be profiled via GC-MS and other technologies to determine the “steroid fingerprint” in MOC, MBT, benign ovarian tumours, and mucinous appendiceal or pseudomyxoma peritoneal cancer.

—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

England, United Kingdom, Wales

Contacts

Public ContactRachel Iles

r.iles@bham.ac.uk0121 414 3344

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 4, 2026